Global Oncology Academy

Treating HCT Patients with CMV: A New Era of Therapy

Treating HCT Patients with CMV: A New Era of Therapy
RestartResume

The emergence of a new form of therapy can help reduce morbidity and mortality associated with CMV infection in HCT recipients.

Available credits: 0.25

Time to complete: 15 minutes

Released:

Valid until:

Take Post-Test

If you’ve already completed the activity.

  • Overview

    The emergence of a new form of therapy that focuses on novel molecular targets will help reduce the morbidity and mortality that’s associated with cytomegalovirus (CMV) infection in hematopoietic stem cell transplant (HCT) recipients. 

    This article will describe this new therapy’s mechanism of action, antiviral activity, and clinical outcomes associated with these newer approaches and explain how clinical practice guidelines and expert recommendations have changed regarding the role of CMV prophylaxis in HCT recipients.

  • Disclosure of Conflicts of Interest

    Disclosure of Conflicts of Interest: 

    In accordance with the ACCME Standards for Commercial Support, Global Learning Collaborative (GLC) requires that individuals in a position to control the content of an educational activity disclose all relevant financial relationships with any commercial interest. GLC resolves all conflicts of interest to ensure independence, objectivity, balance, and scientific rigor in all its educational programs. 

    Faculty: 
    Roy F. Chemaly, MD, MPH, FIDSA, FACP
    Professor of Medicine
    UT MD Anderson Cancer Center
    Houston, TX

    Consulting Fees: Chimerix, Inc., Clinigen, Merck, Oxford Immunotec, Shire
    Contracted Research: Chimerix, Merck, Oxford Immunotec, Shire 

    Reviewers/Content Planners/Authors: 

    • Ann Early has nothing to disclose.
    • Amanda Hilferty has nothing to disclose.
    • Nick Lombardi has ownership interest with Vertex Pharmaceuticals.
    • Brian P. McDonough, MD, FAAFP has nothing to disclose.
    • William Mencia, MD, FACEHP, CHCP has nothing to disclose.
  • Learning Objectives

    After participating in this educational activity, participants should be better able to:

    • Select appropriate CMV preventive approaches in patients undergoing HCT based on patient-specific risk factors.
    • Describe the novel mechanism of action, antiviral activity, and clinical outcomes associated with newer approaches to preventing CMV infections in patients undergoing HCT.
    • Explain how clinical practice guidelines and expert recommendations have changed regarding the role of prophylaxis in CMV-seropositive HCT recipients.
  • Target Audience

    This activity is designed to meet the educational needs of hematologists and oncologists and infectious disease specialists.

  • Accreditation and Credit Designation Statements

    Global Learning Collaborative is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

    Global Learning Collaborative designates this enduring material for a maximum of .25 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

  • Provider(s)/Educational Partner(s)

    Prova Education, designs and executes continuing education founded on evidence-based medicine, clinical need, gap analysis, learner feedback, and more. Our mission is to serve as an inventive and relevant resource for clinical content and educational interventions across a broad spectrum of specialties.

    Prova Education's methodology demonstrates a commitment to continuing medical education and the innovative assessment of its effects. Our goal is clear—to develop and deliver the very best education in the most impactful manner and to verify its results with progressive outcomes research.   

  • Commercial Support

    This activity is supported by an independent educational grant from Merck.

  • Disclaimer

    The views and opinions expressed in this educational activity are those of the faculty and do not necessarily represent the views of GLC and Prova Education. This presentation is not intended to define an exclusive course of patient management; the participant should use his/her clinical judgment, knowledge, experience and diagnostic skills in applying or adopting for professional use any of the information provided herein. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patients’ conditions and possible contraindications or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities. Links to other sites may be provided as additional sources of information. Once you elect to link to a site outside of Prova Education you are subject to the terms and conditions of use, including copyright and licensing restriction, of that site.

    Reproduction Prohibited

    Reproduction of this material is not permitted without written permission from the copyright owner.

Facebook Comments

NEW FEATURES:

Register

We’re glad to see you’re enjoying Global Oncology Academy…
but how about a more personalized experience?

Register for free